biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Does xB3 Work?

<< Previous

Bullboard Posts

Next >>

Comment by TheTruth1234on Aug 21, 2023 6:09pm

66 Views

Post# 35598812

RE:RE:RE:Does xB3 Work?

Boomskid wrote: You missed the point, totally, TT.

You gotta be smart and informed if you're going to play smart and informed.

The point of the xB3 questions was and remains to put the CEOs on the public record. Duh! I discussed that for years, but you likely didn't read it, or even more likely, couldn't understand it.

Frankly, I have worried for years about issues with xB3. My questions to the CEOs were to put them on the record. And I did. So did they in every filing, corporate presentation and all their other documents. My efforts were intended to prevent them from using semantics to mislead investors.

And then in 2020 I found a paper that expressed concern about using the LRP-1 as a transport vector across the BBB because of the ubiquity of that receptor in the CNS. The concern was that too much of the payload would be delivered off tartget. I believe that there may be little likelyhood that Daichi Sankyo/AstraZeneca's Enhertu can be delivered to the CNS by xB3 because the cytotoxin with its neighbouring cell toxic delivery would destroy too many healthy cells.

So don't bother with the "Davenport pumping" nonsense. I was always going after the truth.

Are you being paid to spout this nonsense, TheTruth1234? I mean, attacking me is one thing, but misleading readers about the facts is another.

jd